Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.
Emília Dvoroznáková, Jarmila Porubcová, Viliam Snábel, Peter Fedorocko
Index: Parasitol. Res. 103(4) , 919-29, (2008)
Full Text: HTML
Abstract
The effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) administered separately or with anthelmintic albendazole (ABZ) on cellular immunity of mice with alveolar echinococcosis was studied. The proliferative activity of splenic T and B lymphocytes was the most stimulated after combined L-MTP-PE + ABZ therapy [from weeks 8 to 14 post-infection (p.i.)] that also induced a long-term development of protective Th1 response (the highest serum concentration of IFN-gamma from weeks 8 to 18 p.i.). On the contrary, Th2 response (cytokine IL-5) in infected mice treated with L-MTP-PE was inhibited since week 8 p.i., but a significant long-term decrease in IL-5 concentration was found after combined L-MTP-PE+ABZ therapy until the end of the experiment (until week 26 p.i.). L-MTP-PE stimulated the production of superoxide anion (O2-) by peritoneal macrophages from weeks 8 to 12 p.i., but the highest O2- production was accordingly recorded after therapy L-MTP-PE+ABZ from weeks 8 to 18 p.i. Stimulation of cellular immunity of mice with alveolar echinococcis with L-MTP-PE and an interaction with ABZ's anti-parasitic effect resulted in the greatest and long-term reduction of growth of Echinococcus multilocularis cysts in the host from week 10 p.i. until the end of the experiment.
Related Compounds
Related Articles:
Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma.
2009-08-01
[Expert Rev. Anticancer Ther. 9(8) , 1035-49, (2009)]
1999-04-01
[Cancer Biother. Radiopharm. 14(2) , 121-8, (1999)]
1998-10-01
[Cancer Biother. Radiopharm. 13(5) , 363-8, (1998)]
Effect of MTP on TNF-alpha in perfused rat liver after bacteremia and ischemia/reperfusion.
1998-05-01
[J. Surg. Res. 76(2) , 179-84, (1998)]
2008-02-01
[Expert Rev. Anticancer Ther. 8(2) , 151-9, (2008)]